Illumina Constellation Becomes TruePath Genome

Why It Matters

TruePath Genome lets Illumina retain customers by offering long‑range data on existing instruments, challenging dedicated long‑read competitors and reshaping sequencing budgets.

Key Takeaways

• TruePath Genome priced at $395 per genome
• Uses on‑flowcell tagmentation, eliminating library prep consumables
• Generates haplotype blocks comparable to long‑read platforms
• Reduces sample‑to‑insight time to ~32 hours
• Multiplexing slated for 2027, 5‑mC chemistry 2028

Pulse Analysis

Illumina’s decision to rebrand its Constellation mapped‑read system as TruePath Genome marks a strategic pivot toward delivering long‑range information on its existing NovaSeq X platform. By moving library preparation onto the flowcell, the technology tagmentates high‑molecular‑weight DNA directly in nanowells, allowing the DRAGEN engine to infer proximity of reads and construct haplotype blocks. The $395 per‑genome price point bundles consumables, on‑flowcell prep, and end‑to‑end analysis, positioning TruePath as a turnkey alternative to dedicated long‑read instruments while leveraging labs’ current Illumina investments.

From a competitive standpoint, TruePath directly challenges PacBio HiFi and Oxford Nanopore’s long‑read offerings by promising comparable structural‑variant resolution with a markedly shorter 32‑hour turnaround. The on‑flowcell workflow reduces hands‑on time and eliminates the multi‑microgram DNA inputs that have limited adoption of conventional long‑read platforms. Early clinical case studies, such as those presented by UMC Utrecht, demonstrate the method’s ability to resolve complex disease loci that short‑read pipelines miss. However, independent head‑to‑head benchmarking will be essential, as rivals are likely to scrutinize claims of superiority in repetitive and GC‑biased regions.

The roadmap outlined by Illumina’s CTO foresees multiplexing capabilities in 2027 and the addition of 5‑methyl‑cytosine detection chemistry by 2028, expanding TruePath’s utility beyond human diagnostics to plant, animal and microbial genomics. By embedding DRAGEN analytics on the instrument, Illumina also sidesteps the costly cloud‑compute pipelines that have become a barrier for many laboratories. If the technology lives up to its promises, the $395 price could reshape budgeting decisions, allowing institutions to retain a single sequencing platform for both short‑read and long‑range applications. Stakeholders will watch early adopters closely to gauge real‑world performance and market disruption.